New treatments for brain disease - towards market with a disruptive technology

Purpose and goal

Key2Brain´s technology is based on innovative transport molecules that can be fused to other drugs, in order to significantly increase their uptake into the brain. During the course of the project, we will accelerate our preclinical development with this new brain targeting drug. We intend to treat inflammation in the brain and will, during the course of the project, move from the early preclinical stage towards the clinic and market with this molecule. The aim is to develop a safe and efficient treatment for selected indications related to inflammation affecting the brain.

Expected effects and result

We will advance the company readiness towards the market by investing strongly in preclinical development activities, where we expect to demonstrate effect and proof-of-concept in vivo as well as developing a production process in different stages. In the meantime, preparations for expanding the organization will be made. The organization shall be able to support late preclinical development and preparation for clinical phases, which in the later stages of the project, means a significant growth of the team and investments in the company.

Planned approach and implementation

In this project, we have planned for five stages. The first stage, which has been approved, aims at the milestone: Preclinical validation and first steps towards a process of a drug candidate, indication strategy and market aspects. We will during this first stage establish an upstream and downstream processes, build up analytical methods for characterization and initiate preclinical proof-of-concept studies. In parallel, we will work with indication strategy, target product profile and market analyses.

External links

Hemsida